NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement.
作者信息
Piepiorka-Broniecka Marta, Michalski Tomasz A, Figatowski Tomasz, Wojtowicz Andrzej, Jurowiecki Jaroslaw, Stanska Aleksandra, Rogowski Jan, Jaguszewski Milosz J
机构信息
Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland.
1st Department of Cardiology, Medical University of Gdansk, Poland.
出版信息
Cardiol J. 2022;29(2):355-357. doi: 10.5603/CJ.a2021.0158. Epub 2021 Dec 13.
Abstract
摘要
相似文献
1
NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement.生物人工主动脉瓣置换术后前三个月，新型口服抗凝药与华法林治疗心房颤动的对比研究
Cardiol J. 2022;29(2):355-357. doi: 10.5603/CJ.a2021.0158. Epub 2021 Dec 13.
2
3
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.阿哌沙班对比华法林在伴有既往生物瓣置换或修复的心房颤动患者中的疗效和安全性：来自 ARISTOTLE 试验的结果。
Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
4
New Oral Anticoagulants Versus Warfarin in Atrial Fibrillation After Early Postoperative Period in Patients With Bioprosthetic Aortic Valve.生物瓣主动脉瓣置换术后早期的心房颤动患者中新型口服抗凝药与华法林的比较
Ann Thorac Surg. 2022 Jan;113(1):75-82. doi: 10.1016/j.athoracsur.2021.03.016. Epub 2021 Mar 18.
5
Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis.非维生素 K 拮抗剂与华法林在合并生物瓣心房颤动患者中的应用：系统评价和荟萃分析。
Am J Med. 2022 Feb;135(2):228-234.e1. doi: 10.1016/j.amjmed.2021.08.026. Epub 2021 Oct 8.
6
Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?生物人工主动脉瓣置换术后早期使用华法林进行抗凝治疗是否必要？
J Thorac Cardiovasc Surg. 2005 May;129(5):1024-31. doi: 10.1016/j.jtcvs.2004.11.028.
7
Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves.心房颤动合并生物瓣患者的最佳抗凝治疗。
Kardiol Pol. 2022;80(2):137-150. doi: 10.33963/KP.a2022.0051.
8
9
Meta-analysis of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Bioprosthetic Valves.心房颤动合并生物瓣患者使用直接口服抗凝剂的荟萃分析
Am J Cardiol. 2021 Mar 1;142:140-141. doi: 10.1016/j.amjcard.2020.12.006. Epub 2020 Dec 4.
10
Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing.心脏手术后非维生素 K 口服抗凝剂的使用正在迅速增加。
J Thorac Cardiovasc Surg. 2020 Nov;160(5):1222-1231. doi: 10.1016/j.jtcvs.2019.09.064. Epub 2019 Sep 28.
引用本文的文献
1
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valve Replacement: An Umbrella Review.心房颤动合并生物瓣膜置换患者中直接口服抗凝剂与维生素K拮抗剂的比较：一项伞状综述
J Innov Card Rhythm Manag. 2025 Jul 15;16(7):6355-6373. doi: 10.19102/icrm.2025.16075. eCollection 2025 Jul.
2
Does the type of oral anticoagulant matter for stroke prevention or bleeding in patients with atrial fibrillation after cardiac surgery? A systematic review and meta-analysis.心脏手术后房颤患者预防卒中或出血时，口服抗凝剂的类型重要吗？一项系统评价和荟萃分析。
Eur Heart J Open. 2025 Jun 4;5(3):oeaf062. doi: 10.1093/ehjopen/oeaf062. eCollection 2025 May.
3
A parametric study regarding structural design of a bioprosthetic aortic valve by 3D fluid-structure interaction simulations.一项通过三维流固耦合模拟对生物人工主动脉瓣结构设计进行的参数研究。
Heliyon. 2024 Mar 6;10(6):e27310. doi: 10.1016/j.heliyon.2024.e27310. eCollection 2024 Mar 30.
4
Direct oral anticoagulants in patients with bioprosthetic heart valves.生物人工心脏瓣膜患者使用直接口服抗凝剂的情况。
Intern Emerg Med. 2023 Aug;18(5):1269-1272. doi: 10.1007/s11739-023-03288-7. Epub 2023 May 27.
5
Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis.直接口服抗凝剂在左心生物瓣患者中的应用：系统评价和荟萃分析。
Intern Emerg Med. 2023 Mar;18(2):535-547. doi: 10.1007/s11739-023-03208-9. Epub 2023 Feb 7.
6
Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials.特殊人群中用于预防卒中的直接口服抗凝剂：临床试验之外
Biomedicines. 2023 Jan 4;11(1):131. doi: 10.3390/biomedicines11010131.
本文引用的文献
1
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班在心房颤动合并生物瓣二尖瓣患者中的应用。
N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
2
Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.新型口服抗凝剂与华法林在伴有心房颤动和心脏瓣膜病患者中的比较：系统评价和荟萃分析。
Drugs R D. 2019 Jun;19(2):117-126. doi: 10.1007/s40268-019-0274-z.
3
2017 ESC/EACTS Guidelines for the management of valvular heart disease.2017年欧洲心脏病学会/欧洲心胸外科学会瓣膜性心脏病管理指南。
Eur Heart J. 2017 Sep 21;38(36):2739-2791. doi: 10.1093/eurheartj/ehx391.
4
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.生物瓣膜置换术后房颤管理中达比加群与华法林的比较：DAWA 初步研究
Drugs R D. 2016 Jun;16(2):149-54. doi: 10.1007/s40268-016-0124-1.
5
Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?生物人工主动脉瓣置换术后的最佳血栓预防：仍是一个有争议的问题？
Interact Cardiovasc Thorac Surg. 2012 Jul;15(1):109-14. doi: 10.1093/icvts/ivs102. Epub 2012 Apr 5.
Zotero 插件